Healthcare Reforms Aimed at Preventing Genetic Disorders from Being Passed On to Future Generations Drives the Importance of Prenatal Diagnostics in Maternal Healthcare
The
global market for Prenatal Diagnostics is projected to reach US$6.8 billion by
2022, driven by delayed pregnancies, rising incidence of chromosomal
anomalies in the fetus causing Down’s syndrome and other disorders, and
technological improvements that minimize false negatives and enhance accuracy
in results.
Prenatal testing involves
screening and diagnostic methods carried out during pregnancy for various
purposes, such as determination of fetal sex and identification of potential
genetic and chromosomal abnormalities of the fetus. cff-DNA refers to cell-free
fetal DNA, which escapes into the maternal blood circulation via the placenta,
and offers crucial information about the fetal genetic makeup and links to any
potential disease. Non-Invasive Prenatal Testing (NIPT) technique analyzes
cff-DNA in the maternal blood sample to detect chromosomal aneuploidies, especially
trisomy of the chromosome 21, which is commonly called Down’s syndrome. NIPT is
more accurate than serum screening or ultrasonography and avoids the discomfort
and risk of invasive testing.
The global prenatal diagnostics market is benefiting from
the high risk of chromosomal abnormalities associated with increasing maternal
age, especially across the developed nations where delayed pregnancy is a
common occurrence. Even among the emerging economies of the developing world, increasing
healthcare expenditure, and shifting of childbearing preferences to a later
maternal age are driving growth of prenatal diagnostics. Increased incidences
of Down’s
syndrome, Patau syndrome, Edwards syndrome
(trisomies of chromosomes 21, 13 & 18 respectively), and Turner syndrome
(monosomy x), favors growth in the market. Furthermore, technological
improvements that facilitate elimination or reduction of false negatives and
enhance accuracy in results are expected to further boost the market. Technological
advancements in genomics ensure accuracy of prenatal diagnostics. DNA
sequencing is increasingly carried out via Next-Generation Sequencing (NGS)
platforms.
Massively
Parallel Sequencing (MPS) is a method that entails breaking down a large
sequencing project into smaller projects. Massively parallel sequencing of
maternal plasma enables identification of chromosomal origin of each sequenced
DNA molecule, fetal and maternal, and can detect chromosomal
over-representation or trisomies in the fetus, or even under-representation.
Sequenom’s MaterniT21™, Aria/Roche’s Harmony test, Illumina’s Verifi™, Natera’s
Panorama™, and others including LifeCodexx’ PrenaTest® represent some of the
leading prenatal diagnostic tests.
As stated by the new market research report on Prenatal
Diagnostics, the United States represents
the largest market worldwide. Asia-Pacific ranks as the fastest growing market,
with a CAGR of 6.2% over the analysis period led by significant changes in
birthing timeline among the expanding base of educated working women; better healthcare
awareness; rising disposable income and increased ability to spend on high
quality diagnostic care & services.
Major players in the market
include ANGLE Plc, Berry Genomics Co. Ltd., BGI Genomics, F. Hoffmann-La Roche
Ltd., Hologic Inc., Illumina Inc., Laboratory Corporation of America® Holdings,
Lifecodexx AG, Natera Inc., Quest Diagnostics Inc., Ravgen Inc., and Sequenom
Inc., among others.
The
research report titled "Prenatal
Diagnostics - Market Analysis, Trends, and Forecasts" announced by Global Industry Analysts Inc., provides a
comprehensive review of market trends, growth drivers, mergers and acquisitions,
and other strategic industry activities of major companies worldwide. The
report provides market estimates and projections for geographic markets, such
as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and
Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Latin
America (Brazil, and Rest of Latin America), and Rest of World.
Global Industry
Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.
For
enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.
For cutting edge analyst reviews on top industries
Comments
Post a Comment